Trial record 14 of 26 for:
rhBMP-2 | Industry
Clinical Study of rhBMP-2/BCP With the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease
This study has been completed.
Sponsor:
Medtronic Spinal and Biologics
Information provided by (Responsible Party):
Medtronic Spinal and Biologics
ClinicalTrials.gov Identifier:
NCT01494454
First received: December 12, 2011
Last updated: December 15, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is designed to assess the safety and effectiveness of the rhBMP/BCP/TRSH Spinal System in treatment of the patients with degenerative disc disease.
| Condition | Intervention |
|---|---|
|
Degenerative Disc Disease |
Device: rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System Device: Autograft/TSRH® or autograft/CD HORIZON® Spinal System. |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Clinical Study of Recombinant Human Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With Either the TSRH® Spinal System or the CD Horizon® Spinal System for Posterolateral Lumbar Fusion in Patients With DDD |
Further study details as provided by Medtronic Spinal and Biologics:
Primary Outcome Measures:
- Fusion [ Time Frame: 24 month ] [ Designated as safety issue: No ]
Fusion is defined as:
- Evidence of bridging trabecular bone.
- No evidence of motion as defined by: a. No more than 3mm difference in translation on the lateral flexion/extension radiographs as determined by superimposing the two views, one upon the other; b. Less than 5° difference in angular motion between flexion and extension as seen on the lateral flexion/extension radiographs;
- Absence of radiolucent lines completely through the fusion mass.
- Pain/Disability Status [ Time Frame: 24 month ] [ Designated as safety issue: No ]The self-administered Oswestry Low Back Pain Disability Questionnaire will be used. Success for each individual patient will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score >= 15
Secondary Outcome Measures:
- Neurological status [ Time Frame: 24 month ] [ Designated as safety issue: No ]Neurological status will be assessed preoperatively and postoperatively using a comprehensive neurological status scale. Neurological status is based on four types of measurements (sections): motor, sensory, reflexes and straight leg raise.
- Hip (Donor Site) pain [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- General health status (SF-36) [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- Pain status (back pain, leg pain) [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- Patient satisfaction [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- Patient global perceived effect [ Time Frame: 24 month ] [ Designated as safety issue: No ]
| Enrollment: | 197 |
| Study Start Date: | August 1999 |
| Study Completion Date: | November 2007 |
| Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: rhBMP-2/BCP |
Device: rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System
rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.
Other Name: Recombinant human bone morphogenetic protein
|
| Active Comparator: Autograft |
Device: Autograft/TSRH® or autograft/CD HORIZON® Spinal System.
Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
Other Name: Autogenous bone graft
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g., pain [leg, back, or symptoms in the sciatic nerve distribution], function deficit and/or neurological deficit and radiographic studies (e.g., CT, MRl, X-Ray, etc.) to include one or more of the following:
- instability (defined as angular motion >=5° translation >= 4mm, based on Flex/Ext radiographs);
- osteophyte formation;
- decreased disc height;
- thickening of ligamentous tissue;
- disc degeneration or herniation; and/or
- facet joint degeneration.
- Has preoperative Oswestry score >= 30.
- Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's classification (Meyerding HW, 1932).
- Has one or two adjacent levels from L1 to S1 requiring fusion.
- Is at least 18 years of age, inclusive, at the time of surgery.
- Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
- If female of child-bearing potential, who is not pregnant or nursing, agrees to not become pregnant for 1 year following surgery.
- Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.
Exclusion Criteria:
- Has primary diagnosis of a spinal disorder other than degenerative disc disease with Grade 1 spondylolisthesis at the involved levels.
- Had previous spinal fusion surgical procedure at the involved levels.
- Has a condition that requires postoperative medications that interfere with fusion, such as steroids.
- Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
- Has presence of active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin).
- Has overt or active bacterial infection, either local or systemic.
- Is grossly obese, i.e., weight > 40% over ideal for their age and height.
- Has fever ( temperature > 101°F oral) at the time of surgery.
- Has a documented titanium alloy allergy or intolerance.
- Is mentally incompetent. If questionable, obtain psychiatric consult.
- Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
- Is a prisoner.
- Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
- Is a tobacco user at the time of surgery.
- Has received drugs that may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery ( e.g., NSAIDS, steroids or methotrexate).
- Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
- Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins).
- Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/BCP implantation.
- Has received any previous exposure to any/all BMP's of either human or animal extraction.
- Has a history of severe allergy ( anaphylaxis).
- Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta).
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | Medtronic Spinal and Biologics |
| ClinicalTrials.gov Identifier: | NCT01494454 History of Changes |
| Other Study ID Numbers: | C-9807 |
| Study First Received: | December 12, 2011 |
| Last Updated: | December 15, 2011 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Medtronic Spinal and Biologics:
|
Lumbar degenerative disc disease |
Additional relevant MeSH terms:
|
Spinal Diseases Intervertebral Disk Degeneration Bone Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on May 16, 2013